Mismatched Tech And Demand Behind Korea’s Slow Pharma AI Progress
'Trial And Error' Process
Executive Summary
The new head of South Korea’s AI Drug Development Support Center talks about the country’s activities and market trends in the field, why the otherwise tech-savvy country is still lagging and what is needed to boost collaboration and the availability of big data.
You may also be interested in...
Trial Hot Spot: Australia's Attractions To The Korean Industry
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.